Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Eli Lilly and Company
Juan Pablo Frias; Michael A Nauck; Joanna Van; Mark E Kutner; Xuewei Cui; Charles Benson; Shweta Urva; Ruth E Gimeno; Zvonko Milicevic; Deborah Robins; Axel Haupt